Dapagliflozin in patients with type 2 diabetes mellitus

Therapeutic Advances in Endocrinology and Metabolism

Volumn 6, Issue 1, 2015, Pages 29-41

  Filippatos, Theodosios D ^a   Liberopoulos, Evangelos N ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

adverse effects; blood pressure; body weight; dapagliflozin; diabetes mellitus; drug interactions; metabolic effects; sodium glucose linked transporter type 2 inhibitors

Indexed keywords

DAPAGLIFLOZIN; DIGOXIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLUCOSE; GLUCOSE TRANSPORTER 2; INSULIN; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; VALSARTAN; VOGLIBOSE; WARFARIN;

BLOOD PRESSURE REGULATION; BODY WEIGHT; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; GENITAL TRACT INFECTION; GLUCOSE METABOLISM; GLUCOSE REABSORPTION; GLYCEMIC CONTROL; HUMAN; HYPOTENSION; HYPOVOLEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SEVERE RENAL IMPAIRMENT; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 84922809151     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018814558243     Document Type: Review

References (78)

1. Agouridis A. Rizos C. Elisaf M. Filippatos T. (2013) Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? Rev Diabet Stud 10: 171–190.
2. American Diabetes Association (2014) Standards of medical care in diabetes. Diabetes Care 37(Suppl. 1): S14–S80.
3. Bailey C. Gross J. Hennicken D. Iqbal N. Mansfield T. List J. (2013) Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11: 43.
4. Bailey C. Gross J. Pieters A. Bastien A. List J. (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223–2233.
5. Bailey C. Iqbal N. T'joen C. List J. (2012) Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14: 951–959.
6. Balakumar P. Sundram K. Dhanaraj S. (2014) Dapagliflozin: glucuretic action and beyond. Pharmacol Res 82: 34–39.
7. Ballestri S. Lonardo A. Bonapace S. Byrne C. Loria P. Targher G. (2014) Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20: 1724–1745.
8. Bolinder J. Ljunggren O. Johansson L. Wilding J. Langkilde A. Sjostrom C. et al. (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16: 159–169.
9. Bolinder J. Ljunggren O. Kullberg J. Johansson L. Wilding J. Langkilde A. et al. (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97: 1020–1031.
10. Boulton D. Kasichayanula S. Keung C. Arnold M. Christopher L. Xu X. et al. (2013) Simultaneous oral therapeutic and intravenous (1) (4)C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol 75: 763–768.
11. Burki T. (2012) FDA rejects novel diabetes drug over safety fears. Lancet 379: 507.
12. Carlson G. Tou C. Parikh S. Birmingham B. Butler K. (2011) Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study. Diabetes Ther 2: 123–132.
13. Clar C. Gill J. Court R. Waugh N. (2012) Systematic review of SGLT 2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2: e001007.
14. de Nicola L. Gabbai F. Liberti M. Sagliocca A. Conte G. Minutolo R. (2014) Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis 64: 16–24.
15. European Commission (2012) Dapagliflozin summary of product characteristics. Available at: http://ec.europa.eu/health/documents/community-register/2012/20121112124487/anx_124487_en.pdf (accessed 28 July 2014).
16. FDA Advisory Committee Meeting (2011) FDA briefing document. NDA 202293. Available at: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262994.pdf (accessed 2 August 2014).
17. Ferrannini E. (2010) Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrol Dial Transplant 25: 2041–2043.
18. Ferrannini E. Ramos S. Salsali A. Tang W. List J. (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33: 2217–2224.
19. Filippatos T. Athyros V. Elisaf M. (2014) The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors. Expert Opin Drug Metab Toxicol 10: 787–812.
20. Filippatos T. Elisaf M. (2010 a) Combination drug treatment in obese diabetic patients. World J Diabetes 1: 8–11.
21. Filippatos T. Elisaf M. (2010 b) Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol 2: 139–142.
22. Filippatos T. Elisaf M. (2011) Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol 3: 265–267.
23. Filippatos T. Elisaf M. (2013 a) Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes 4: 190–201.
24. Filippatos T. Elisaf M. (2013 b) High density lipoprotein and cardiovascular diseases. World J Cardiol 5: 210–214.
25. Filippatos T. Kiortsis D. Liberopoulos E. Georgoula M. Mikhailidis D. Elisaf M. (2005) Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 21: 1997–2006.
26. Gazi I. Filippatos T. Tsimihodimos V. Saougos V. Liberopoulos E. Mikhailidis D. et al. (2006) The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids 41: 647–654.
27. Goring S. Hawkins N. Wygant G. Roudaut M. Townsend R. Wood I. et al. (2014) Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 16: 433–442.
28. Gosmanov A. Wall B. Gosmanova E. (2014) Diagnosis and treatment of diabetic kidney disease. Am J Med Sci 347: 406–413.
29. Grandy S. Hashemi M. Langkilde A. Parikh S. Sjostrom C. (2014 a) Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab 16: 645–650.
30. Grandy S. Langkilde A. Sugg J. Parikh S. Sjostrom C. (2014 b) Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years. Int J Clin Pract 68: 486–494.
31. Imamura A. Kusunoki M. Ueda S. Hayashi N. Imai Y. (2013) Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes. Diabetes Ther 4: 41–49.
32. Jabbour S. Hardy E. Sugg J. Parikh S. ; Study 10 Group (2014) Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 37: 740–750.
33. Ji L. Ma J. Li H. Mansfield T. T'joen C. Iqbal N. et al. (2014) Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther 36: 84–100 e109.
34. Johnsson K. Ptaszynska A. Schmitz B. Sugg J. Parikh S. List J. (2013 a) Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27: 473–478.
35. Johnsson K. Ptaszynska A. Schmitz B. Sugg J. Parikh S. List J. (2013 b) Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27: 479–484.
36. Kasichayanula S. Chang M. Hasegawa M. Liu X. Yamahira N. Lacreta F. et al. (2011 a) Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 13: 357–365.
37. Kasichayanula S. Chang M. Liu X. Shyu W. Griffen S. Lacreta F. et al. (2012) Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther 29: 163–177.
38. Kasichayanula S. Liu X. Griffen S. Lacreta F. Boulton D. (2013 a) Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obes Metab 15: 280–283.
39. Kasichayanula S. Liu X. Lacreta F. Griffen S. Boulton D. (2014) Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 53: 17–27.
40. Kasichayanula S. Liu X. Pe Benito M. Yao M. Pfister M. Lacreta F. et al. (2013 b) The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 76: 432–444.
41. Kasichayanula S. Liu X. Shyu W. Zhang W. Pfister M. Griffen S. et al. (2011 b) Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 13: 47–54.
42. Kasichayanula S. Liu X. Zhang W. Pfister M. Lacreta F. Boulton D. (2011 c) Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther 33: 1798–1808.
43. Kasichayanula S. Liu X. Zhang W. Pfister M. Reele S. Aubry A. et al. (2011 d) Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT 2 inhibitor, in healthy subjects. Diabetes Obes Metab 13: 770–773.
44. Katsiki N. Athyros V. Karagiannis A. Mikhailidis D. (2011 a) Current treatment for nonalcoholic fatty liver disease. Expert Opin Pharmacother 12: 2141–2142.
45. Katsiki N. Athyros V. Karagiannis A. Mikhailidis D. (2011 b) Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 9: 698–705.
46. Komoroski B. Vachharajani N. Boulton D. Kornhauser D. Geraldes M. Li L. et al. (2009) Dapagliflozin, a novel SGLT 2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 85: 520–526.
47. Lambers Heerspink H. de Zeeuw D. Wie L. Leslie B. List J. (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15: 853–862.
48. Leong A. Dasgupta K. Chiasson J. Rahme E. (2013) Estimating the population prevalence of diagnosed and undiagnosed diabetes. Diabetes Care 36: 3002–3008.
49. List J. Woo V. Morales E. Tang W. Fiedorek F. (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32: 650–657.
50. Ljunggren O. Bolinder J. Johansson L. Wilding J. Langkilde A. Sjostrom C. et al. (2012) Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 14: 990–999.
51. Matheny C. Lamb M. Brouwer K. Pollack G. (2001) Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21: 778–796.
52. Merovci A. Solis-Herrera C. Daniele G. Eldor R. Fiorentino T. Tripathy D. et al. (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124: 509–514.
53. Mudaliar S. Henry R. Boden G. Smith S. Chalamandaris A. Duchesne D. et al. (2014) Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther 16: 137–144.
54. Nauck M. Del Prato S. Meier J. Duran-Garcia S. Rohwedder K. Elze M. et al. (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34: 2015–2022.
55. Niskanen L. Laaksonen D. Nyyssonen K. Alfthan G. Lakka H. Lakka T. et al. (2004) Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 164: 1546–1551.
56. Obermeier M. Yao M. Khanna A. Koplowitz B. Zhu M. Li W. et al. (2010) In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 38: 405–414.
57. Oliva R. Bakris G. (2014) Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 8: 330–339.
58. Reilly T. Graziano M. Janovitz E. Dorr T. Fairchild C. Lee F. et al. (2014) Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther 5: 73–96.
59. Rosenstock J. Vico M. Wei L. Salsali A. List J. (2012) Effects of dapagliflozin, an SGLT 2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35: 1473–1478.
60. Seifalian A. Filippatos T. Joshi J. Mikhailidis D. (2010) Obesity and arterial compliance alterations. Curr Vasc Pharmacol 8: 155–168.
61. Shah N. Deeb W. Choksi R. Epstein B. (2012) Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy 32: 80–94.
62. Sheikh-Ali M. Raheja P. Borja-Hart N. (2013) Medical management and strategies to prevent coronary artery disease in patients with type 2 diabetes mellitus. Postgrad Med 125: 17–33.
63. Strojek K. Yoon K. Hruba V. Elze M. Langkilde A. Parikh S. (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13: 928–938.
64. Strojek K. Yoon K. Hruba V. Sugg J. Langkilde A. Parikh S. (2014) Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther 5: 267–283.
65. Tahrani A. Barnett A. (2010) Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. Diabetes Ther 1: 45–56.
66. Terami N. Ogawa D. Tachibana H. Hatanaka T. Wada J. Nakatsuka A. et al. (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PloS ONE 9: e100777.
67. Tsouli S. Liberopoulos E. Mikhailidis D. Athyros V. Elisaf M. (2006) Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 55: 1293–1301.
68. US FDA (2012) FDA declined dapagliflozin. US Food and Drug Administration. Available at: http://www.medscape.com/viewarticle/757175 (accessed 1 August 2014).
69. US FDA (2014) FDA approves dapagliflozin. US Food and Drug Administration. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm (accessed 1 August 2014).
70. Ussher J. Sutendra G. Jaswal J. (2012) The impact of current and novel anti-diabetic therapies on cardiovascular risk. Future Cardiol 8: 895–912.
71. Vallon V. Platt K. Cunard R. Schroth J. Whaley J. Thomson S. et al. (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22: 104–112.
72. van Haalen H. Pompen M. Bergenheim K. Mcewan P. Townsend R. Roudaut M. (2014) Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig 34: 135–146.
73. Vasilakou D. Karagiannis T. Athanasiadou E. Mainou M. Liakos A. Bekiari E. et al. (2013) Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159: 262–274.
74. Whaley J. Tirmenstein M. Reilly T. Poucher S. Saye J. Parikh S. et al. (2012) Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT 2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 5: 135–148.
75. Wilding J. Norwood P. T'joen C. Bastien A. List J. Fiedorek F. (2009) A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32: 1656–1662.
76. Wilding J. Woo V. Rohwedder K. Sugg J. Parikh S. ; Dapaglifozin 006 Study Group (2014) Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 16: 124–136.
77. Wilding J. Woo V. Soler N. Pahor A. Sugg J. Rohwedder K. et al. (2012) Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 156: 405–415.
78. Zhang L. Feng Y. List J. Kasichayanula S. Pfister M. (2010) Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 12: 510–516.